Tuning the Antigen Density Requirement for CAR T-cell Activity
Top Cited Papers
- 1 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 10 (5), 702-723
- https://doi.org/10.1158/2159-8290.CD-19-0945
Abstract
Insufficient reactivity against cells with low antigen density has emerged as an important cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that modulate the threshold for antigen recognition. We demonstrate that CD19 CAR activity is dependent upon antigen density and that the CAR construct in axicabtagene ciloleucel (CD19-CD28 xi) outperforms that in tisagenlecleucel (CD19-4-1BB xi) against antigen-low tumors. Enhancing signal strength by including additional immunoreceptor tyrosine-based activation motifs (ITAM) in the CAR enables recognition of low-antigen-density cells, whereas ITAM deletions blunt signal and increase the antigen density threshold. Furthermore, replacement of the CD8 hinge-transmembrane (H/T) region of a 4-1BB xi CAR with a CD28-H/T lowers the threshold for CAR reactivity despite identical signaling molecules. CARs incorporating a CD28-H/T demonstrate a more stable and efficient immunologic synapse. Precise design of CARs can tune the threshold for antigen recognition and endow 4-1BB xi-CARs with enhanced capacity to recognize antigen-low targets while retaining a superior capacity for persistence. SIGNIFICANCE: Optimal CAR T-cell activity is dependent on antigen density, which is variable in many cancers, including lymphoma and solid tumors. CD28 xi-CARs outperform 4-1BB xi-CARs when antigen density is low. However, 4-1BB xi-CARs can be reengineered to enhance activity against low-antigendensity tumors while maintaining their unique capacity for persistence.Other Versions
Funding Information
- NIH (U54-CA232568-01, P01CA217959-01, 5P30CA124435)
- Stanford University School of Medicine
- Hyundai Hope On Wheels
- St. Baldrick's Stand Up To Cancer (SU2C-AACR-DT-27-17)
- Virginia and D.K. Ludwig Fund for Cancer Research
- Parker Institute for Cancer Immunotherapy
- German Cancer Aid (P-91650709)
- NIH (R35 (1R35GM130332))
- Howard Hughes Medical Institute
- American Society of Hematology
- NIH (T32GM007365)
- Jane Coffin Childs
- Howard Hughes Medical Institute
This publication has 76 references indexed in Scilit:
- Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical TrialsPLOS ONE, 2013
- A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)OncoImmunology, 2012
- Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modelingBlood, 2011
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsBlood, 2010
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in HumansTransplantation and Cellular Therapy, 2010
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBlood, 2008
- Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia XenograftsClinical Cancer Research, 2007
- T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cellsBlood, 2006
- CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor EnhancesIn vivoPersistence and Antitumor Efficacy of Adoptively Transferred T CellsCancer Research, 2006